This Study Tests Whether BI 409306 Prevents Patients With Schizophrenia From Becoming Worse. This Study Looks at How Well Patients Tolerate BI 409306 and How Effective it is Over 6 Months

A Phase II Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Orally Administered BI 409306 During a 28-week Treatment Period as Adjunctive Therapy to Antipsychotic Treatment for the Prevention of Relapse in Patients With Schizophrenia.

The objective of the study is to investigate the efficacy, safety and tolerability of BI 409306 once daily compared with placebo given for 28 weeks in patients with schizophrenia on antipsychotic treatment. The study is designed to show superiority of BI 409306 over placebo in preventing relapse of schizophrenia symptoms.

Study Overview

• Status: Terminated
• Conditions: Schizophrenia
• Intervention / Treatment: Drug: BI 409306; Drug: Placebo

• Study Type: Interventional
• Enrollment (Actual): 264
• Phase: Phase 2

Contacts and Locations

Study Locations

• Canada
  • Alberta
    • Calgary, Alberta, Canada, T2N 4Z6
      • University of Calgary
  • British Columbia
    • Penticton, British Columbia, Canada, V2A 4M4
      • Dr. Alexander McIntyre Inc.
    • Vancouver, British Columbia, Canada, V7T 1C5
      • The Medical Arts Health Research Group
  • Ontario
    • Chatham, Ontario, Canada, N7L 1C1
      • Chatham-Kent Clinical Trials Research Centre
    • Toronto, Ontario, Canada, M6J 1H4
      • Centre for Addiction and Mental Health (CAMH)
  • Quebec
    • Montreal, Quebec, Canada, H1N 3M5
      • IUSMM Institut Universitaire en Sante Mentale de Montreal
• France
  • Montpellier, France, 34295
    • HOP la Colombière
  • Paris, France, 75674
    • GHU Paris Psychiatrie et Neurosciences
  • Rennes, France, 35703
    • HOP Guillaume Régnier
  • Saint-Priest-en-Jarez, France, 42270
    • HOP Nord
  • Toulon, France, 83100
    • HOP Sainte Musse
• Japan
  • Aichi, Toyoake, Japan, 470-1192
    • Fujita Health University Hospital
  • Aichi, Toyoake, Japan, 470-1168
    • Okehazama Hospital Fujita Kokoro Care Center
  • Chiba, Ichikawa, Japan, 272-8516
    • National Center for Global Health and Medicine Kohnodai Hospital
  • Fukuoka, Fukuoka, Japan, 814-0180
    • Fukuoka University Hospital
  • Fukuoka, Fukuoka, Japan, 819-0037
    • Kuramitsu Hospital
  • Kanagawa, Atsugi, Japan, 243-0201
    • Soushu Hospital
  • Kanagawa, Kawasaki, Japan, 214-0014
    • Kishiro Mental Clinic
  • Nara, Kashihara, Japan, 634-8522
    • Nara Medical University Hospital
  • Saga, Kanzaki-gun, Japan, 842-0192
    • National Hospital Organization Hizen Psychiatric Medical Center
  • Tokyo, Kodaira, Japan, 187-8851
    • National Center Neurology and Psychiatry
• Korea, Republic of
  • Gwangju, Korea, Republic of, 61453
    • Chonnam National University Hospital
  • Seongnam, Korea, Republic of, 13620
    • Seoul National University Bundang Hospital
  • Seoul, Korea, Republic of, 03080
    • Seoul National University Hospital
• Spain
  • Santander, Spain, 39008
    • Hospital Universitario Marques de Valdecilla
• Taiwan
  • Tainan, Taiwan, 704
    • NCKUH
  • Taoyuan, Taiwan, 33058
    • Taoyuan Psychiatric Center
• United States
  • Arizona
    • Phoenix, Arizona, United States, 85012
      • Alea Research
  • California
    • Costa Mesa, California, United States, 92626
      • ATP Clinical Research, Inc.
    • Garden Grove, California, United States, 92845
      • Collaborative Neuroscience Network, LLC (CNS)
    • Glendale, California, United States, 91206
      • Behavioral Research Specialists, LLC
    • Lemon Grove, California, United States, 91945
      • Synergy East
    • Los Angeles, California, United States, 90095
      • University of California Los Angeles
    • Oceanside, California, United States, 92056
      • Excell Research Inc.
    • Orange, California, United States, 92868
      • Orange County Neuropsychiatric Research Center LLC
    • Torrance, California, United States, 90502
      • Collaborative Neuroscience Network, LLC (CNS)
  • Florida
    • Hallandale Beach, Florida, United States, 33009
      • MD Clinical
    • Hialeah, Florida, United States, 33012
      • Reliable Clinical Research
    • Maitland, Florida, United States, 32751
      • Meridien Research
    • North Miami, Florida, United States, 33161
      • Behavioral Clinical Research, Inc.
    • Orlando, Florida, United States, 32810
      • Meridien Research
  • Georgia
    • Atlanta, Georgia, United States, 30331
      • Atlanta Center
  • Illinois
    • Chicago, Illinois, United States, 60612
      • Alam Medical Research, Inc.
  • Louisiana
    • Lake Charles, Louisiana, United States, 70629
      • Lake Charles Clinical Trials LLC
    • Monroe, Louisiana, United States, 71201
      • Clinical Trials of America, LLC
  • Michigan
    • Ann Arbor, Michigan, United States, 48105
      • Michigan Clinical Research Institute PC
  • Mississippi
    • Flowood, Mississippi, United States, 39232
      • Precise Research Centers
  • Missouri
    • Saint Charles, Missouri, United States, 63304
      • St. Charles Psychiatric Associates & Midwest Research Group
    • Saint Louis, Missouri, United States, 63128
      • PsychCare Consultants Research
    • Saint Louis, Missouri, United States, 63125
      • Arch Clinical Trials
  • Nevada
    • Las Vegas, Nevada, United States, 89102
      • Altea Research Institute
  • New Jersey
    • Berlin, New Jersey, United States, 08009
      • Hassman Research Institute
  • New York
    • Cedarhurst, New York, United States, 11516
      • Neurobehavioral Research, Inc.
    • New York, New York, United States, 10032
      • New York State Psychiatric Institute
    • New York, New York, United States, 10036
      • Manhattan Behavioral Medicine PLLC
  • Texas
    • Austin, Texas, United States, 78754
      • Community Clinical Research, Inc.
    • Irving, Texas, United States, 75062
      • University Hills Clinical Research
    • Richardson, Texas, United States, 75080
      • Pillar Clinical Research, LLC
    • Richmond, Texas, United States, 77407
      • @Health Texas

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 55 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• International Statistical Classification of Diseases and Related Health Problems, 10th Revision (ICD-10) diagnosis of schizophrenia >= one year prior to randomisation.
• Outpatients in the stable phase of illness, as assessed by the investigator after review of medical records or documented discussion with treating clinician.
• Patients currently taking a stable dose of antipsychotic medication(s) for at least 12 weeks prior to randomisation.
• Detectable level of current antipsychotic medication(s) in plasma from blood drawn at Visit 1 (unless no assay is available for the antipsychotic(s) currently prescribed).

• Patients who have experienced at least 2 relapses within the past 5 years or at least 1 relapse if they were diagnosed less than 3 years ago. Relapse is defined as the patient having any of the following using the above number of relapses and time frames:

  • Hospitalization for psychosis (involuntary or voluntary admission), intensive outpatient therapy or use of home treatment as an alternative to hospitalization (verified via medical record).
  • Emergency Department visit for worsening schizophrenia symptoms (verified via medical record).
  • Deliberate self-injury and/or violent behaviour resulting in significant injury to another person or property (verified by police record or treating mental health provider written record or documented phone conversation).
  • Change in the patient's antipsychotic medication or increase in antipsychotic medication dosage due to worsening of schizophrenia symptoms (verified by pharmacy records or treating mental health provider written record or documented phone conversation).
• Clinical Global Impressions-Severity (CGI-S) score ≤4 at Visit 1 and 2.
• Positive and Negative Syndrome Scale (PANSS) total score <80 and a score of ≤ 4 on individual PANSS items conceptual disorganization, hallucinatory behavior, suspiciousness, and unusual thought content at Visit 1.
• Of full age (according to local legislation, usually ≥ 18 years) and ≤ 55 years at the time of informed consent.
• Patients must have an identified informant who will be consistent throughout the study.
• Patients who report living at the same address for the 3 months prior to randomisation.

• Male or female patients.

  -- Female patients of childbearing potential must be ready and able to use highly effective methods of birth control per International Conference on Harmonisation (ICH) M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. Patients must agree to use birth control throughout the trial and for at least 28 days after treatment has ended. Acceptable methods of birth control include combined estrogen-progestin oral, intravaginal or transdermal contraceptives, progestogen-only oral, injectable or implantable contraceptives, intrauterine devices (IUDs), intrauterine hormone releasing systems (IUSs), bilateral tubal occlusion, vasectomized sexual partner, and complete sexual abstinence (if acceptable by local health authorities) is allowed when this is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptom-thermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.

• Male patients who are able to father a child must be ready and able to be abstinent or use adequate contraception for the duration of study participation and for at least 28 days after treatment has ended.
• Signed and dated written informed consent in accordance with International Conference on Harmonisation - Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial. If the patient has a legal representative, then this legal representative must give written informed consent as well.

Exclusion criteria:

• Patients treated with more than two antipsychotic medications (including more than two dosage forms).
• Patients who are currently being treated with clozapine, or who have been treated with clozapine in the past 5 years.
• Patients with a categorical diagnosis of another current major psychiatric disorder per the Mini-international neuropsychiatric Interview (M.I.N.I.).
• Homicidal behaviour (in the investigator's judgement) in the past 2 years.
• Any suicidal behavior in the past 2 years (i.e. actual attempt, interrupted attempt, aborted attempt, or preparatory acts or behavior).
• Any suicidal ideation of type 4 or 5 in the Columbia Suicide Severity Rating Scale (CSSRS) in the past 3 months (i.e. active suicidal thought with intent but without specific plan, or active suicidal thought with plan and intent).
• In the judgment of the investigator, any clinically significant finding from the physical examination or laboratory value deviating from normal or any evidence of a clinically significant concomitant disease or any other clinical condition that would jeopardize a patient's safety while participating in the clinical trial.
• Other known neurological diseases (including but not limited to any kind of seizures or stroke).
• Any documented active or suspected malignancy or history of malignancy within 5 years prior to screening, except appropriately treated basal cell carcinoma of the skin or in situ carcinoma of uterine cervix.
• Planned elective surgery requiring general anesthesia, or hospitalization for more than 1 day during the study period.
• Significant history of drug or alcohol dependence or abuse (Substance Use Disorder as defined in Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) or ICD-10) within the last six months prior to informed consent. (Not including caffeine or nicotine).
• Patients who must or wish to continue the intake of restricted medications or any drug considered likely to interfere with the safe conduct of the trial.
• Patients taking strong or moderate CYP1A2 inhibitors who are also a CYP2C19 Poor Metabolizer (PM). Patients taking medication known to be strong or moderate inhibitors of CYP1A2 must be prospectively genotyped to ensure they are not poor metabolizers of CYP2C19. (A list of CYP1A2 and CYP2C19 inhibitors can be found in the Investigator Site File (ISF)).
• Patients taking strong or moderate CYP1A2 inhibitors who are also taking concomitant strong or moderate CYP2C19 inhibitors. (A list of CYP1A2 and CYP2C19 inhibitors can be found in the ISF)
• Patients with a history of moderate to severe hepatic impairment (Child-Pugh B / C).
• Patients with a history of moderate to severe renal impairment (Stage 3 - 5).
• Women who are pregnant, nursing, or who plan to become pregnant while in the trial.
• In the judgment of the investigator, inability of the patient to comply with the clinical trial procedures.
• Currently enrolled in another investigational device or drug study, or less than 6 months from Visit 1 since ending another investigational device or drug study(s), or participation in > 2 investigational drug clinical trials in the past 2 years.
• Previous randomisation in any BI 409306 study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: BI 409306 50 mg; 1 film-coated tablet of 50 milligrams (mg) of BI 409306 plus 1 tablet of 25 mg matching placebo were administered orally once daily for a treatment period of 28 weeks, followed by a withdrawal/taper period of 7 days, followed by a follow-up period of 3 weeks.	Drug: BI 409306; 28 week treatment period
Experimental: BI 409306 25 mg; 1 film-coated tablet of 25 milligrams (mg) of BI 409306 plus 1 tablet of 50 mg matching placebo were administered orally once daily for a treatment period of 28 weeks, followed by a withdrawal/taper period of 7 days, followed by a follow-up period of 3 weeks.	Drug: BI 409306; 28 week treatment period
Placebo Comparator: Placebo; 1 film-coated tablet of 25 milligrams (mg) of matching Placebo plus 1 tablet of 50 mg matching placebo were administered orally once daily for a treatment period of 28 weeks, followed by a withdrawal/taper period of 7 days, followed by a follow-up period of 3 weeks.	Drug: Placebo; 28 week treatment period

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence Rate of First Relapse After 28 Weeks of Treatment	The incidence rate of first relapse after 28 weeks of treatment is reported. For each treatment group, the incidence rate was calculated as the number of events / sum of the observational time (patient year) over all participants in this treatment group.	28 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Positive Symptoms Score After 28 Weeks of Treatment	Positive and Negative Syndrome Scale (PANSS): assesses the severity of psychotic symptoms and progression of disease. The PANSS positive symptoms score is the sum of scores from 7 Items where each item has a minimum score 1 (better outcome) and maximum score 7 (worse outcome). The PANSS positive symptoms score ranges from 7 (less severe the disease) to 49 (more severe the disease).	At baseline and at Week 28.
Change From Baseline in Clinical Global Impressions-Severity (CGI-S) Scale Score After 28 Weeks of Treatment	Clinical Global Impressions-Severity (CGI-S): One-item evaluation completed by the clinician to measure the severity of psychopathology. The CGI-S score ranges from 1 (normal) through to 7 (most severely ill). The higher the score, the worse the psychopathology.	At baseline and at Week 28
Patient Global Impressions-Improvement (PGI-I) Scale Score After 28 Weeks of Treatment	Patient Global Impressions-Improvement (PGI-I): One-item evaluation completed by the patient to assess their overall evaluation of his/her status compared to how they felt at randomisation. The PGI-I score ranges from 1 (Very much better) through to 7 (Very much worse). The higher the score, the worse the improvement.	At Week 28
Incidence Rate of Suicidal Ideation and Behaviour (Assessed by Columbia Suicide Severity Rating Scale (C-SSRS)) After 28 Weeks of Treatment	Columbia Suicide Severity Rating Scale (C-SSRS): suicide risk assessment. At a minimum, the interview consists of 2 screening questions related to suicidal ideation and 4 related to suicidal behavior, and may be expanded to up to 17 items in case of positive responses. Free text entries are allowed. Suicidal behavior is collected in nominal scale as presence/absence of actual attempts, non-suicidal self-injurious behavior, interrupted attempts, aborted attempts, preparatory acts or behavior, and any suicidal behavior. Suicidal ideation is rated on a 6-point scale from 0 (No ideation present) to 5 (Active ideation with plan and intent). A score of 4 or 5 on this scale indicates serious suicidal ideation. For each treatment group, the incidence rate was calculated as the number of events / sum of the observational time (patient year) over all participants in this treatment group.	28 weeks
Change From Baseline in Personal and Social Performance Scale (PSP) Score After 28 Weeks of Treatment	Personal and Social Performance scale (PSP): The PSP is a 100-point, single item, clinician rated scale to assess 4 domains of social functioning (Four domains over the past month: (1) socially useful activities, (2) personal and social relationships, (3) self-care and (4) disturbing and aggressive behaviors.) in patients with schizophrenia. The PSP score is a single score ranging from 1 to 100. Higher scores represent better personal and social functioning.	At baseline and at Week 28
Incidence Rate of New Prescription or Increase in Dose of an Ongoing Antipsychotic Medication	The incidence rate of new prescription or increase in dose of an ongoing antipsychotic medication is reported. For each treatment group, the incidence rate was calculated as the number of events / sum of the observational time (patient year) over all participants in this treatment group.	28 weeks

Collaborators and Investigators

• Sponsor: Boehringer Ingelheim

Publications and helpful links

Helpful Links

• Related Info

Study record dates

Study Major Dates

• Study Start (Actual): December 7, 2017
• Primary Completion (Actual): March 10, 2021
• Study Completion (Actual): March 31, 2021

Study Registration Dates

• First Submitted: November 20, 2017
• First Submitted That Met QC Criteria: November 20, 2017
• First Posted (Actual): November 22, 2017

Study Record Updates

• Last Update Posted (Actual): May 12, 2022
• Last Update Submitted That Met QC Criteria: April 19, 2022
• Last Verified: April 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Mental Disorders; Schizophrenia Spectrum and Other Psychotic Disorders; Schizophrenia; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Phosphodiesterase Inhibitors; BI 409306
• Other Study ID Numbers: 1289-0049; 2017-002369-23 (EudraCT Number)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No